Comorbid mood, psychosis, and marijuana abuse disorders: A theoretical review

Journal of Addictive Diseases

Volumn 28, Issue 4, 2009, Pages 309-319

  Wilson, Natascha ^a   Cadet, Jean Lud ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Cannabis; Depression; Neuropsychiatry; Schizophrenia

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS;

BRAIN BLOOD FLOW; CANNABIS ADDICTION; CLINICAL FEATURE; COGNITION; COMORBIDITY; HUMAN; MOOD DISORDER; NEUROIMAGING; PSYCHOSIS; REVIEW;

AFFECTIVE DISORDERS, PSYCHOTIC; COGNITION DISORDERS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MARIJUANA ABUSE; MOOD DISORDERS; NEUROPSYCHOLOGY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 75149142843     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880903182960     Document Type: Review

References (155)

1. Overview of Findings from the 2002 National Survey on Drug Use and Health, 2002. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration Office of Applied Studies, NHSDA Series H-21, DHHS Publication No. SMA03- 3774). Rockville, MD.
2. Epstein JF. Substance dependence, abuse and treatment: findings from the 2000 National Household Survey on Drug Abuse. NHSDA Series A-16, DHHS Publication no. SMA 02-3642. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies 2002. http://www.DrugAbuse Statistics.SAMSHA.gov.
3. Iversen L. Long-term effects of exposure to cannabis. Curr Opin Pharmacol 2005; 5:69-72.
4. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19:233-238
5. Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol 2002; 42:28S-33S.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
7. World Health Organization. ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva, Switzerland: Author, 1992.
8. Lichtman AH, Martin BR. Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 2002; 42:20S-27S.
9. Basavarajappa BS.Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007; 5:81-97.
10. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77:299-318.
11. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR. Mechoulam R, Pertwee RG. International Union of Pharmacology XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161-202.
12. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPSJ 2005; 7:EE625- 54.
13. D'Souza DC, Braley G, Blasie R, Vendetti M, Oliver S, Pittman B, Ranganathan, M, Bhakta S, Zimolo Z,Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects ofΔ- 9-tetrahydrocannabinol in humans. Psychopharmacology 2008; 198:587-603.
14. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005; 81:263-284
15. Laviolette SR, Grace AA. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdale inputs. J Neurosci 2006; 26:6458-6468
16. Herman H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451-460
17. Maccarrone M, Wenger T. Effects of cannabinoids on hypothalamic and reproductive function. Handb Exp Pharmacol 2005; 168:555-571
18. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 1998; 5:417-431
19. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178:116-122
20. Thomas H. Psychiatric symptoms in cannabis users. Br J Psychiatry 1993; 163:141-149
21. Thacore VR, Shukla SRP. Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 1976; 383-386
22. Tennant FS, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27:133-136
23. Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000; 8:483-492
24. Crowley TJ, MacDonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal and reinforcing effects among adolescents with conduct disorder symptoms and substance use disorders. Drug Alcohol Depend 1998; 50:27-37.
25. Mikulich SK, Hall SK, Whitmore EA, Crowley TJ. Concordance between DSM-III R and DSM-IV diagnoses of substance use disorders in adolescents. Drug Alcohol Depend 2001; 61:237-248
26. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment formarijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 1998; 6:419-426
27. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J SubstAbuse Treat 2001; 21:55-64.
28. Stephens RS, Babor TF, Kadden R, Miller M. The marijuana treatment project: rationale, design and participant characteristics. Addiction 2002; 97:109-124
29. O'Leary DS, Block RI, FlaumM, Schultz SK, Ponto LLB,Watkins GL, Hurtig RR, Andreasen NC, Hichwa RD. Acute marijuana effects on rCBF and cognition: a PET study. NeuroReport 2000; 11:3835-3841
30. Chang L, Yakupov R, Cloak C, Ernst T. Marijuana use in associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 2006; 129:1096-1112
31. Hart C, McCance-Katz EF, Kosten TR. Pharmacotherapies used in common substance use disorders. In: Tims FM, Leukefeld CG, Platt JJ, eds. Relapse and recovery in addictions. New Haven: Yale University Press, 2001:303-333.
32. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LLB, Ghoneim MM, Arndt S, Hurtig RR, Watkins GL, Hall JA, Nathan PE,Andreasen NC. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav 2002; 72:237-250
33. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimaging 2004; 23:914920.
34. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2000; 59:1337-1343
35. Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 2005; 26:480-492
36. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 2006; 185:358-368
37. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59:1337-1343
38. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimaging 2004; 23:914-920
39. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 25:909-915
40. Solowij N. Cannabis and cognitive functioning. Cambridge: Cambridge University Press, 1998.
41. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J of Obesity 2006; 30:S13-8.
42. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, Hollister L. Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain:a study with positron emission tomography and 18F- 2-fluoro-2-dexoyglucous. Psychiatry Res Neuroimaging 1991; 40:69-78.
43. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 1992; 12:750-758
44. Block RI, O'Leary DS, Erhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11:491-496
45. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug and Alcohol Dependence 2005; 77:23-30.
46. Herning RI, Better WE, Tate K, Cadet JL. Cerebrovascular perfusion in marijuana users during month of monitored abstinence. Neurology 2005; 64:488-493
47. Schaffer A, Cairney J, Cheung A, Veldhuizen S, Levitt A. Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics. Can J Psychiatry 2006; 51:9-16.
48. Grant BF, Stinson FS, Hasin DS, Dawson DA, Chou SP, RuanWJ, Huang B. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66:1205-1215 (Pubitemid 41546498)
49. Kessler RC, Burglund P, Demler O, Jin R, Koretz D, Merikangas, KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105
50. Baĺazs J, Benazzi F, Rihmer Z, Rihmer A, Akiskal KK, Akiskal HS. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006; 91:133-138
51. Murphy FC, SahakianBJ. Neuropsychology of bipolar disorder. Br J Psychiatry 2001; 178:120-127
52. Fountoulakis NK, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007; 6: 27.
53. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21:911-936
54. Wolfe J, Granholm E, Butters N, Sanders E, Janowsky D. Verbal memory deficits associated with major affective disorders: A comparison of unipolar and bipolar patients. J Affect Disord 1987; 13:83-92.
55. Calev A, Nigal D, Chazan S. Retrieval from semantic memory using meaningful and meaningless constructs by depressed, stable bipolar and manic patients. Br J Clin Psychology 1989; 28:67-73.
56. Sweeney JA, Kmiec JA, Kupfer DJ. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry 2000; 48:674-684
57. Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, Kleinman JE, Weinberger, DR. Contrasts between patients with affective disorders and patients with schizophrenia on neuropsychological test battery. Am J Psychiatry 1993; 150:1355-1362
58. van Gorp WG, Althuler L, Theberge DC, Wilkins J, Dixon W. Cognitive impairment in euthymic bipolar patientswith andwithout prior alcohol dependence. Arch Gen Psychiatry 1998; 55:41-46
59. Strawkowski SM, DelBello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 2005; 10:105-116
60. Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin in Psychiatry 2006; 19:25-33.
61. Hwang J, Lyoo IK, Dager ST, Friedman SD, Oh JS, Lee JY, Kim SJ, Dunner DL, Renshaw PF. Basal ganglia shape alterations in bipolar disorder.AmJ Psychiatry 2006; 163:276-285
62. Drevets WC, Price JL, Simpson JR, Todd RD, Reich T, Vannier M, Raichle ME. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 386: 824-827
63. Agarwal N, Bellani M, Perlini C, Rambaldelli G, Atzori M, Cerini R, Vecchiato F, Pozzi Mucelli R, Andreone N, BalestrieriM, Tansella M, Brambilla P. Increased fronto-temporal perfusion in bipolar disorder. J of Affective Disorder 2008; 110:106-114
64. Blumberg HP, Stern E, Martinez D, Ricketts S, de Asis J, White T, Epstein J, McBride PA, Eidelberg D, Kocsis JH, Silbersweig DA. Increased anterior cingulate and caudate activity in bipolar mania. Biol Psychiatry 2000; 48:1045-1052
65. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME. Glucose metabolism in the amygdale in depression: relationship to diagnostic subtype and plasma Cortisol levels. Pharmacol Biochem Behav 2002; 71:431-447
66. National Institution of Mental Health. Schizophrenia: with addendum schizophrenia January 2007 (NIH Publication No. 06-3517). Rockville, MD: Author.
67. Gold JM,Weinberger DR. Cognitive deficits and the neurobiology of schizophrenia. Curr Opin in Neuro 1995; 5:225-230
68. Bernard M, Raḿon AJ, Rubio-Terŕes C, Rejas J. Cost-effective analysis of schizophrenia relaspse prevention: an economic evaluation of the ZEUS (Ziprasidone- Extended-Use-In-Schizophrenia) study in Spain. Clin Drug Investig 2006; 26:447-457
69. McCombs JS, Nichol MB, Johnstone BM, Stimmel GL, Shi J, Smith R. Antipsychotic drug use pattern and the cost of treating schizophrenia. Psychiatr Serv 2000; 51:525-527
70. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1:179-186
71. Metzer HY. Biological studies in schizophrenia. Schizophr Bull 1987; 13:77-111.
72. Kuipers E, Peters E, Bebbington P. Schizophrenia. In: Carr A, Mcnulty M, eds. The handbook of adult clinical psychology: an evidence-based practice approach. New York: Taylor and Francis, 2006:843-896
73. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR. The relationship between dorsolateral prefrontal neuronal n-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000; 22:125-132
74. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand Suppl 2000; 400:11-16
75. Bradley A. Working memory. Science 1992; 255:556-559
76. Fleming K, Goldberg TE, Blinks S, Randolph C, Gold JM, Weinberger DR. Visuospatial working memory in patients with schizophrenia. Biol Psychiat 1997; 41:43-49
77. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin NorthAm 1993; 16:295-312.
78. Goldberg TE, Karson CN, Leleszi JP, Weinberger DR. Intellectual impairment in adolescent psychosis: a controlled psychometric study. Schizophr Res 1988; 1:261-266
79. Goldberg TE, Ragland D, Torrey F, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 1990; 47:1066-1072
80. Goldberg TE, Gold JM, Greenberg R, Griffin A, Schulz C, Pickar D, Kleinman JE, Weinberger DR. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry 1993; 150:1355-1362
81. Baxter RD, Liddle PF. Neuropsychological deficits associated with schizophrenic syndromes. Schizophr Res 1998; 30:239-249
82. Moritz S, Andresen B, Jacobsen D, Mersmann K, Wilke U, Lambert M, Naber D, Krausz M. Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics. Eur Psychiatry 2001; 16:354-361
83. Nieuwenstein MR, Aleman A, de Haan EHF. Relationship between symptoms dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. J Psychiatric Res 2001; 35:119-125
84. Aleman A, Hijman R, de Haan EH, Kahn RS.Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999; 156:1358-1366
85. Liddle PF, MorrisDL. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 1991; 158:340-345
86. Moritz S, Heeren D, Andresen B, Krausz M. An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia. Psychiatry Res 2001; 101:23-31.
87. O'Leary DS, FlaumM, KesslerML, Flashman LA, Arndt S, Andreasen NC. Cognitive correlates of the negative disorganized and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000; 12:4-15.
88. Weinberger DR, Berman KF, Zec RF. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. I: regional cerebral blood flow (rCBF) evidence. Arch Gen Psychiatry 1986; 43:114-125
89. Andreasen NC, Flaum M, Arndt S. The comprehensive assessment of symptoms and history (CASH): an instrument for assessing psychopathology and diagnosis. Arch Gen Psychiatry 1992; 49:615-623
90. Schuepbach D, Merlo MCG, Goenner F, Staikov I, Mattle HP, Kierks T, Brenner HD. Cerebral hemodynamic response induced by the Tower of Hanoi puzzle and the Wisconsin Card Sorting Test. Neuropsychologia 2002; 40:39-53.
91. Schuepbach D, Bader JP, Hell D, Baumgartner RW. Cerebral hemodynamics and processing speed during category learning. NeuroReport 2004; 15:1195-1198
92. Schuepbach D, Hell D, Baumgartner RW. Lateralization of cerebral hemodynamics during Wisconsin Card Sorting Test: a functional transcranial Doppler sonography study. Clin Neurophysiol 2005; 116:1041-1048
93. Frauenfelder BA, Schuepbach D, Baumgartner RW, Hell D. Specific alterations of cerebral hemodynamics during a planning task: a transcranial Doppler sonography study. Neuroimage 2004; 22:1223-1230
94. Shenton ME, Dickey CC, FruminM,McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49:1-52.
95. Kelsoe JR, Cadet JL, Pickar D, Weinberger DR. Quantitative neuroanatomy in schizophrenia. Arch Gen Psychiatry 1988; 45:533-541
96. Mathew RJ, Partrain CL, Prakash R, Kulkarni MV, Logan TP, Wilson WH. A study of the septum pellucidum and corpus callosum in schizophrenia with MR imaging. Acta Psychiatr Scand 1985; 72:414-421
97. McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, Shenton ME. MRI anatomy of schizophrenia. Biol Psychiatry 1999; 45:1099-1119
98. Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung A, Phillips L,McGorry PD. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schiz Bulletin 2005; 31:672-696
99. Mitropoulou V, Goodman M, Sevy S, Elman I, New AS, Iskander EG, Silverman JM, Breier A, Siever LJ. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schiz Research 2004; 70:27-31.
100. Catafau AM, Parellada E, Lomeña FJ, Bernardo M, Pav́ia J, Ros D, Setoain J, Gonzalez-Moncĺus E. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO-SPECT patterns in your neuroletptic naïve patients with acute disease. J Nucl Med 1994; 35:935-941
101. Hoyer S, Österreich K. Blood flow and oxidative metabolism of the brain in patients with schizophrenia. Psychiatria Clin 1975; 8:304-313
102. Owega A, Klingelhöfer J, Sabir O, Kunert HJ, Albers M, Sass, H. Cerebral blood flow velocity in acute schizophrenic patients: a transcranial Doppler ultrasonography study. Stroke 1998; 29:1149-1154
103. Brodie JD, Christman DR, Corona JF, Fowler JS, Gomez-Mont F, Jaeger J, Micheels PA, Rotrosen J, Russell JA, Volkow ND,Wikler A,Wolf AP,Wolkin A. Patterns of metabolic activity in the treatment of schizophrenia. Ann Neurol 1984; 15:166-169
104. Lewis SW, Ford RA, Syed GM, Reveley AM, Toone BK. A controlled study of Tc-99m-HMPAO single-photon emission imaging in chronic schizophrenia. Psychol Med 1992; 22:27-35.
105. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, Gomez-Mont F, Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985; 142:564-571
106. Paulman RG, Devous MD Sr, Gregory RR, Herman JH, Jennings L, Bonte FJ, Nasrallah HA, Raese JD. Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. Biol Psychiatry 1990; 27:377-399
107. Kessler RC. Epidemiology of psychiatric comorbidity. In: Tsuang MT, Tohen M, Zahner GEP, eds. Textbook of psychiatric epidemiology. New York: Wiley-Liss, 1995:179-197.
108. Negrete JC. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 2003; 18:14-21.
109. Jablensky A, McGrath J, Herman H, Castle D, Gureje O, Evans M, Carr V, Morgan V, Korten A, Harvey C. Psychotic disorders in urban areas: an overview of the study of low prevalence disorders. Aust N Z J Psychiatry 2003; 34:221-236
110. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) Study. JAMA 1990; 264:2511-2518
111. Carey MP, Carey KB, Meisler AW. Psychiatric symptoms in mentally ill chemical abusers. J Nerv Ment Dis 1991; 179:136-138
112. Fagiolini A, Frank E, Houck PR, Mallinger AG, Swartz HA, Buysse DJ, Ombao H, Kupfer DJ. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63:528-533
113. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160:112-117
114. Sharma R, Marker HR. Mortality in affective disorder. J Affect Disord 1994; 31:91-96
115. Sharma R, Marker HR, Ballenger JC. Mortality in affective disorder. In Talbott JA, ed.Year book of psychiatry and applied mental health.Chicago: Mosby Year Book, Inc, 1996:296-297.
116. D'Souza, DC, Abi-Saab WM, Madonick S, et al.Δ9-tetrahydocannabinol effects in schizophrenia: implications for cognition, psychosis and addiction. Biol Psychiatry 2005; 57:594-608.
117. Sevy S, Kay SR, Opler L, van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990; 178:642-648
118. Halikas JA, Goodwin DW, Guze SB. Marihuana use and psychiatric illness. Arch Gen Psychiatry 1972; 27:162-165
119. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187:9-20. (Pubitemid 41002508)
120. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56:803-807
121. Maccarone M, Gubellini P, Bari M, Picconi B, Battista N, CentonzeD, BernardiG, Finazzi-AgroA, Calabresi P. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 2003; 85:1018-1025
122. Giuffrida A, Parsons LH, Kerr TM, Rodŕiguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2:358-363
123. Rodŕiguez de Fonseca F, Del Arco I, Mart́in- Caldeŕon JL, Gorriti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5:483-501.
124. ShermanC. Lithium displays impressive antisuicidal effects. Clinical Psychiatry News, 2001. http://findarticles. com/p/articles/mi hb4345/is 10 29/ai n28870181.
125. Gearon JS, Bellack AS. Addiction services: women with schizophrenia and co-occurring substance use disorders: an increased risk for violent victimization and HIV. Community Ment Health J 1999; 35:401-419
126. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187:306-313
127. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35:93-100.
128. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156:319-327
129. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64:57-64.
130. El-Mallakh RS,Brown C. The effect of extreme marijuana use on the long-term course of bipolar I illness: a single case study. J Psychoactive Drugs 2007; 39:201-202
131. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998; 30:171-177
132. Gruber JA, Pope HG Jr, Brown ME. Do patients use marijuana as an antidepressant? Depression 1996; 4:77-80.
133. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187:9-20. (Pubitemid 41002508)
134. Dixon L, Haas G, Weiden P, Sweeney J, Francis A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr Bull 1990; 16:69-79.
135. Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci 1997, 22:99-104.
136. Addington J, Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr Scand 1997; 96:329-333
137. Strakowski SM, DelBello MP, Fleck DE, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007; 64:57-64.
138. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35:93-100.
139. Liraud F, Veroud H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 2002; 28:160-168
140. Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003; 28:48-54.
141. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts neurocognition at 10-year follow-up. Schizophr Res 2005; 75:135-137
142. Jockers-Scherübl MC, Wolf T, Radzei N, Schlattmann P, Rentzsch J, Gomez-Carrillo de Castro A, Kuhl K-P. Cannabis induces different cognitive changes schizophrenic patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1054-1063
143. Sevy S, Burdick KE, Visweswaraiah H, Abdelmessih S, Lukin M, Yechiam E, Bechara A. Iowa Gambling Task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007; 92:74-84.
144. Cahill CM, Malhi GS, Ivanovski B, Lagopoulos J, Cohen M. Cognitive compromise in bipolar disorder with chronic cannabis use: cause or consequence? Expert Rev Neurotherapeutics 2006; 6:591-598
145. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulated grey-matter deficits and cannabis use in firstepisode schizophrenia. Br J Psychiatry 2007; 190:230-236
146. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res 2008; 99:1-6.
147. Rais M, CahnW, Van Haren N, Schnack H, Caspers E, Hulshoff Pol H, Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165:490-496
148. Jockers-Scherübl MC,MatthiesU, Danker-HopfeH, Lang UE,Mahlberg R, Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drugnaive schizophrenic patients. J Psychopharmacol 2003; 17:439-445
149. Degenhardt L, HallW, LynskeyM. Testing hypotheses about the relationship between cannabis and psychosis. Drug Alcohol Depend 2003; 71:37-48.
150. Medina KL, Nagel BJ, Park A, McQueeny T, Tapert S. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J Child Psychol Psychiatry 2007; 48:592-600.
151. Depp C, Lebowitz BD. Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry 2007; 19:531-539
152. Donovan SJ, Nunes EV. Treatment of comorbid affective and substance use disorders: therapeutic potential of anticonvulsants. Am J Add 1998; 7:210-220
153. Rousaville BJ. DSM-V Research agenda: substance abuse/psychosis comorbidity. Schizophr Bull 2007; 33:947-952
154. Havassay BE, Alvidrez J, Owen KK. Comparisons of patients with comorbid psychiatric and substance use disorders: implication for treatment and service delivery. Am J Psychiatry 2004; 161:139-145
155. Cadet JL, Bolla K, Herning RI. Neurological assessment of marijuana users. Methods Mol Med 2006; 123:255-268